Payment overview · 2025
General Payments
$131.18
6 reported records · 4 companies
Healthcare provider profile · identity verified
Eugene Daniel Harasym, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COVINGTON TOWNSHIP, PA · NPI 1144267790
Verified facts
What the public records show
CMS Open Payments records show Eugene Daniel Harasym, M.D. received $131.18 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.30 | 44.4% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $37.54 | 28.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.89 | 13.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.45 | 13.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $131.18 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 686 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 590 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 397 | 91 |
| Metformin Hcl | Metformin Hcl | 363 | 78 |
| Omeprazole | Omeprazole | 360 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 290 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 67 |
| Lisinopril | Lisinopril | 280 | 77 |
| Alprazolam | Alprazolam | 253 | 67 |
| Gabapentin | Gabapentin | 219 | 50 |
| Furosemide | Furosemide | 204 | 44 |
| Simvastatin | Simvastatin | 184 | 36 |
| Lorazepam | Lorazepam | 176 | 48 |
| Clonidine Hcl | Clonidine Hcl | 168 | 38 |
| Methylprednisolone | Methylprednisolone | 155 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 32 |
| Meloxicam | Meloxicam | 151 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 45 |
| Potassium Chloride | Potassium Chloride | 141 | 30 |
| Azithromycin | Azithromycin | 140 | 108 |
| Eliquis | Apixaban | 119 | 27 |
| Irbesartan | Irbesartan | 115 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 25 |
| Glipizide | Glipizide | 102 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 29 |
| Amoxicillin | Amoxicillin | 89 | 67 |
| Doxazosin Mesylate | Doxazosin Mesylate | 88 | 21 |
| Tramadol Hcl | Tramadol Hcl | 88 | 28 |
| Diazepam | Diazepam | 87 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 26 |
| Allopurinol | Allopurinol | 80 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 19 |
| Atenolol | Atenolol | 70 | 19 |
| Glipizide Er | Glipizide | 70 | 18 |
| Pregabalin | Pregabalin | 69 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 19 |
| Losartan Potassium | Losartan Potassium | 67 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 19 |
| Etodolac | Etodolac | 66 | 30 |
| Prednisone | Prednisone | 66 | 33 |
| Trazodone Hcl | Trazodone Hcl | 66 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 20 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Linzess | Linaclotide | 59 | suppressed |
| Ozempic | Semaglutide | 59 | 13 |
| Famotidine | Famotidine | 57 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 11 |
| Montelukast Sodium | Montelukast Sodium | 50 | 12 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 27 |
| Ramipril | Ramipril | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 14 |
| Topiramate | Topiramate | 42 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 15 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 39 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 14 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 11 |
| Baclofen | Baclofen | 36 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 21 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 12 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 21 |
| Temazepam | Temazepam | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 22 |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Glyburide | Glyburide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Oxaprozin | Oxaprozin | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131.18 · 6 records | PFIZER INC. | ABRYSVO, COMIRNATY, CREON, LINZESS, PREVNAR 20, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error